Drug Discovery 2021 After the Storm: Re-connect, Re-invent, Re-imagine
Poster
67

A chemoenzymatic solution for cell-permeable therapeutic macrocycles

Abstract

A chemoenzymatic solution for cell-permeable therapeutic macrocycles Current drugs address only ca. 30% of the estimated 3000 disease-relevant targets. Many of these untapped therapeutic applications are intracellular protein-protein interactions (PPIs). The two common classes of drugs, small molecules and biologics, are not a universal solution to all drug discovery challenges. GyreOx is exploiting this opportunity using its proprietary discovery platform (‘MACRO’) to create unique Gyrocycle(TM) highly modified macrocyclic peptides. These compounds combine the target-engagement power of biologics with the cell-entry ability of small molecules. GyreOx’s platform technology is a combined chemistry / synthetic biology process, protected by 4 patent applications, allowing rapid access to novel and drug-like macrocycles for hit-to-lead drug discovery.

supporting document

Hosted By

ELRIG

The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis

Get the App

Get this event information on your mobile by
going to the Apple or Google Store and search for 'myEventflo'
iPhone App
Android App
www.myeventflo.com/2374